Colon cancer diagnoses rise among younger adults

A 21-year-old Pennsylvania college student, Katie Davis, says she spent months with intermittent upper-abdominal pain before a colonoscopy revealed stage 2 colon cancer, according to Business Insider. Her case sits inside a broader medical headline that has become hard to ignore: colorectal cancer diagnoses are rising among younger adults in several high-income countries, even as overall colorectal cancer rates in older groups have fallen with screening.

The first analytical question is whether “more cancer” is the same as “more dangerous cancer.” Earlier and more frequent imaging, more endoscopy, and lower thresholds for investigating symptoms can pull diagnoses forward in time and inflate incidence. A surge in colonoscopies among people in their 20s and 30s would be expected to find more early-stage lesions, including some that might never have progressed to lethal disease within a normal lifespan. That does not mean the increase is an illusion; it means the trend must be split by stage at diagnosis, tumour location (proximal versus distal colon and rectum), and histology. A real rise driven by exposures would tend to show up across multiple datasets and, crucially, would not be limited to early-stage findings.

The second question is what could plausibly move population risk curves in a few decades. Obesity and metabolic disease have risen sharply in the same cohorts now showing higher early-onset incidence, and insulin signalling and chronic inflammation are biologically relevant to colorectal carcinogenesis. Diet has also shifted toward ultra-processed foods, higher energy density, and lower fibre intake—factors associated in observational research with colorectal risk, though separating diet from correlated behaviours is notoriously difficult. Antibiotic exposure is another candidate mechanism: altering gut microbiota early in life could change inflammatory tone and metabolite profiles for years, but the evidence base remains mixed and confounded by the infections that prompt antibiotic use.

Screening policy adds a third layer: incentives. Lowering the screening age expands a large, mostly healthy population into a system that is paid per test, per biopsy, and per follow-up procedure. The benefit is catching aggressive cancers earlier; the cost is overdiagnosis, complications, and a pipeline of surveillance colonoscopies that can crowd out higher-risk patients if capacity is fixed. None of this is settled by individual stories, which are powerful precisely because they are not denominators.

Davis’s account ends with surgery and months of chemotherapy complicated by side effects, including episodes of vision loss she associated with oxaliplatin. The epidemiology question her case raises is narrower than the public debate: whether the rising counts in the young reflect earlier detection, different tumour biology, or a genuine shift in exposure—and which datasets can separate those possibilities before screening becomes the default answer.